@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix beldoc: .
@prefix rdfs: .
@prefix rdf: .
@prefix xsd: .
@prefix dce: .
@prefix pav: .
@prefix np: .
@prefix belv: .
@prefix prov: .
@prefix Protein: .
@prefix mgi: .
@prefix geneProductOf: .
@prefix hasPart: .
@prefix ProteinComplex: .
@prefix species: .
@prefix occursIn: .
@prefix pubmed: .
@prefix orcid: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
sub:_1 geneProductOf: mgi:95586;
a Protein: .
sub:_2 hasPart: sub:_3, sub:_4;
a ProteinComplex: .
sub:_3 geneProductOf: mgi:95691;
a Protein: .
sub:_4 geneProductOf: mgi:87912;
a Protein: .
sub:_5 occursIn: species:10090;
rdf:object sub:_2;
rdf:predicate belv:decreases;
rdf:subject sub:_1;
a rdf:Statement .
sub:assertion rdfs:label "p(MGI:Fst) -| complex(p(MGI:Mstn),p(MGI:Acvr2b))" .
}
sub:provenance {
beldoc: dce:description "Approximately 61,000 statements.";
dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
dce:title "BEL Framework Large Corpus Document";
pav:authoredBy sub:_7;
pav:version "1.4" .
sub:_6 prov:value "The purified C-terminal myostatin dimer was capable of binding the activin type II receptors, Act RIIB and, to a lesser extent, Act RIIA. Binding of myostatin to Act RIIB could be inhibited by the activin-binding protein follistatin and, at higher concentrations, by the myostatin propeptide";
prov:wasQuotedFrom pubmed:11459935 .
sub:_7 rdfs:label "Selventa" .
sub:assertion prov:hadPrimarySource pubmed:11459935;
prov:wasDerivedFrom beldoc:, sub:_6 .
}
sub:pubinfo {
this: dcterms:created "2014-07-03T14:29:57.400+02:00"^^xsd:dateTime;
pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}